Bifogade filer
SenzaGen 2025 Annual Report
Kurs
-6,57%
Likviditet
0,32 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2027-02-18 | 07:30 | Bokslutskommuniké 2026 |
| 2026-11-05 | 07:30 | Kvartalsrapport 2026-Q3 |
| 2026-08-20 | 07:30 | Kvartalsrapport 2026-Q2 |
| 2026-05-13 | N/A | X-dag ordinarie utdelning SENZA 0.00 SEK |
| 2026-05-12 | N/A | Årsstämma |
| 2026-05-12 | 07:30 | Kvartalsrapport 2026-Q1 |
| 2026-02-13 | - | Bokslutskommuniké 2025 |
| 2025-11-05 | - | Kvartalsrapport 2025-Q3 |
| 2025-08-20 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-15 | - | X-dag ordinarie utdelning SENZA 0.00 SEK |
| 2025-05-14 | - | Årsstämma |
| 2025-05-14 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-13 | - | Bokslutskommuniké 2024 |
| 2024-11-08 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-22 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-16 | - | X-dag ordinarie utdelning SENZA 0.00 SEK |
| 2024-05-15 | - | Årsstämma |
| 2024-05-15 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-14 | - | Bokslutskommuniké 2023 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-05 | - | X-dag ordinarie utdelning SENZA 0.00 SEK |
| 2023-05-04 | - | Årsstämma |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-08-18 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-06 | - | X-dag ordinarie utdelning SENZA 0.00 SEK |
| 2022-05-05 | - | Årsstämma |
| 2022-02-11 | - | Bokslutskommuniké 2021 |
| 2021-08-19 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-06 | - | X-dag ordinarie utdelning SENZA 0.00 SEK |
| 2021-05-05 | - | Årsstämma |
| 2021-02-18 | - | Bokslutskommuniké 2020 |
| 2020-08-20 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-11 | - | X-dag ordinarie utdelning SENZA 0.00 SEK |
| 2020-05-08 | - | Årsstämma |
| 2020-02-13 | - | Bokslutskommuniké 2019 |
| 2019-12-18 | - | Extra Bolagsstämma 2019 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-16 | - | X-dag ordinarie utdelning SENZA 0.00 SEK |
| 2019-05-15 | - | Årsstämma |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-08-22 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-09 | - | X-dag ordinarie utdelning SENZA 0.00 SEK |
| 2018-05-08 | - | Årsstämma |
| 2018-02-14 | - | Bokslutskommuniké 2017 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
SenzaGen has today published its 2025 Annual Report. A digital copy can be downloaded at www.senzagen.com or read via the link below.
To request a printed copy, please email name and address to IR@senzagen.com.
Contacts
Peter Nählstedt, President and CEO, SenzaGen AB
Email: peter.nahlstedt@senzagen.com | Tel: +46 46-275 62 00
Tina Dackemark Lawesson, VP Marketing & Communications
Email: tina.lawesson@senzagen.com | Tel: +46 46-275 62 00
About us
SenzaGen is a fast‑growing company in the field of non‑animal chemical safety testing. Through ground-breaking innovations that better reflect human biology, the company works toward its vision of advancing and protecting human health while replacing the use of animals in testing. With GLP‑certified laboratories in Sweden and Italy, SenzaGen is driving the shift toward safer and more ethically sustainable testing practices. At the center of the offering is the company’s unique GARD® platform, which combines genomics and machine learning to deliver highly reliable decision‑support data for assessing skin and respiratory sensitization. SenzaGen’s strategy combines commercial focus, regulatory progress, and innovation to support long‑term profitable growth. SenzaGen is headquartered in Lund, Sweden, with subsidiaries in Italy and the United States. For more information, visit www.senzagen.com.
SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company’s Certified Adviser.